Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00766168 · ClinicalTrials.gov registry record · NA
High Refractive Index Material 510(k)
A NA study, sponsored by CooperVision International Limited (CVIL).
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
NCT00766168 is a NA study that has completed, run by CooperVision International Limited (CVIL). The registered enrollment target is 76 participants.
The verdict
NCT00766168, a NA study, has completed, sponsored by CooperVision International Limited (CVIL).
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the substantial equivalence of the HDS HI 1.54™ to the paflufocon C material control lenses to correct myopia and hyperopia with and without astigmatism. The purpose of the study is to profile the outcome endpoints and the patient acceptance of this Class II medical device.
Interventions
- OTHER HDS HI 1.54; pahrifocon A
- DEVICE FluoroPerm 30 RGP; paflufocon C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00766168
The ClinicalTrials.gov registry entry for NCT00766168 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CooperVision International Limited (CVIL), which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HDS HI 1.54; pahrifocon A is the first listed.
NCT00766168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00766168 about?
NCT00766168 is a clinical study titled "High Refractive Index Material 510(k)". The purpose of this study is to establish the substantial equivalence of the HDS HI 1.54™ to the paflufocon C material control lenses to correct myopia and hyperopia with and without astigmatism. The purpose of the study is to profile the outcome endpoints and the patient acceptance of this Class II...
What is the current status of trial NCT00766168?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2008-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00766168?
The interventions under investigation include: HDS HI 1.54; pahrifocon A (OTHER), FluoroPerm 30 RGP; paflufocon C (DEVICE).
Who is sponsoring clinical trial NCT00766168?
This trial is sponsored by CooperVision International Limited (CVIL), which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.